Masimo's Commercial Exhibit Draws More Than 2,500 Conference Attendees
IRVINE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Masimo, the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that 13 new independent and objective clinical studies presented at the American Society of Anesthesiology (ASA) Annual Meeting in Orlando, Fla., October 19-21, 2008, found Masimo SET(R) and Masimo Rainbow SET(R) technologies to be crucial in providing clinicians with an early indication of their patients' deteriorating health status in numerous clinical settings, which may allow earlier intervention and prevention of adverse clinical outcomes.
In addition, Masimo's commercial exhibit attracted over 2,500 anesthesiologists from the U.S. and around the world. Anesthesiologists visiting the commercial exhibit marveled at Masimo noninvasive hemoglobin (SpHb(TM)), the first-and-only technology capable of continuously monitoring hemoglobin status. Continuous monitoring of anemic status with Masimo SpHb may allow clinicians to make earlier and better treatment decisions, such as detecting blood loss earlier to initiate more timely transfusions in some patients and avoiding unnecessary blood transfusions in others.
Select Clinical Study Highlights
Continuous Pulse Ox Impacts Early Detection of Physiological
Abnormalities in Post-Surgical Patients(1), a clinical evaluation led by
Dr. George Blike at Dartmouth-Hitchcock Medical Center in Lebanon, New
Hampshire, compared clinical data, patient outcomes and nursing
satisfaction before and after implementation of Masimo Patient
SafetyNet(TM) -- a remote monitoring and wireless clinician notification
system -- on a 36-bed post-surgical care unit. Findings during the
three-month evaluation -- covering 2,587 total patient days -- showed an 80
percent decrease in distress codes and rescue activations, and a 50 percent
decrease in ICU transfers for Masimo Pati
|SOURCE Masimo Corporation|
Copyright©2008 PR Newswire.
All rights reserved